公司概覽
業務類別 Biotechnology
業務概覽 Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
公司地址 301 Carnegie Center Drive, Suite 304, Princeton, NJ, USA, 08540
電話號碼 +1 609 495-2200
傳真號碼 +1 609 495-2202
公司網頁 https://www.palatin.com
員工數量 25
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Stephen Thomas Wills, C.P.A. Chief Financial Officer, Principal Accounting Officer, Chief Operating Officer, Executive Vice President, Secretary and Treasurer 美元 670.00K 28/09/2026
Dr. Carl Spana,PhD Chief Executive Officer, President and Director 美元 721.00K 28/09/2026
 
董事會成員
董事會 職務 更新日期
Ms. Arlene M. Morris Independent Director 28/09/2026
Dr. Alan W. Dunton,M.D. Independent Director 28/09/2026
Dr. Carl Spana,PhD Chief Executive Officer, President and Director 28/09/2026
Dr. John K.A. Prendergast,PhD Non-Executive Chairman of the Board 28/09/2026
 
所屬ETF (更新日期: 07/11/2026 03:02)
代號 名稱 佔比% ▼ 持有日期
IWCiShares Micro-Cap ETF0.27%30/10/2026
ITOTiShares Core S&P Total US Stock Mkt ETF<0.000001%06/03/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.